Merck & Co., Inc. MRK
- Market cap
- $365.4B
- P/E
- 119×
Follow MRK
Merck & Co., Inc. (MRK) EV/Sales
As of 25 September 2026, Merck & Co., Inc. (MRK) trades at a EV/Sales of 6.2×. Over the past ten years it has ranged from 3.3× (May 2025) to 6.5× (August 2026); the current reading is higher than 100% of that period. That is above the Drug Manufacturers General industry median of 4.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Annual
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 4.5× | 6.99% |
| FY2024 | 4.2× | (18.62%) |
| FY2023 | 5.2× | 4.23% |
| FY2022 | 5.0× | 12.69% |
| FY2021 | 4.4× | (14.07%) |
| FY2020 | 5.2× | (13.84%) |
| FY2019 | 6.0× | 23.76% |
| FY2018 | 4.9× | 22.17% |
| FY2017 | 4.0× | (6.30%) |
| FY2016 | 4.2× | 9.89% |
Quarterly
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 5.4× | 5.51% |
| Mar 2026 | 5.1× | 13.16% |
| Dec 2025 | 4.5× | 26.33% |
| Sep 2025 | 3.6× | 2.19% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| PFE Pfizer Inc. compare | 3.4× |
| NVO Novo Nordisk A/S compare | 3.6× |
| AZN AstraZeneca PLC compare | 4.6× |
| NVS Novartis AG compare | 5.6× |
| MRK Merck & Co., Inc. | 6.2× |
| JNJ Johnson & Johnson compare | 6.8× |
| GILD Gilead Sciences, Inc. compare | 6.9× |
| AMGN Amgen Inc. compare | 7.0× |
| ABBV AbbVie Inc. compare | 8.3× |
| Drug Manufacturers General industry median | 4.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.2× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)
More on MRK
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement